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A rare case of renal thrombotic
microangiopathy associated with
Castleman’s disease
Anubha Mutneja1, L. Nicholas Cossey2, Helen Liapis2,3 and Ying Maggie Chen1*
Abstract
Background: Castleman’s disease (CD) is an uncommon, heterogeneous lympho-proliferative disorder leading to
high circulating levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). Renal involvement has
been only described in a limited number of small studies. Herein, we report a rare case of renal thrombotic
microangiopathy (TMA) associated with CD and investigate the podocyte expression of VEGF in the renal biopsy
prior to initiation of treatment.
Case presentation: An 18-year-old male presented with fever, diarrhea, diffuse lymphadenopathy, ascites and
acute kidney injury. Laboratory tests for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
were negative. The kidney biopsy showed TMA. An excisional lymph node biopsy was consistent with CD, plasma
cell variant. Immunofluorescence staining showed suppressed podocyte VEGF expression. Chemotherapy that
inhibits production of inflammatory mediators including IL-6 and VEGF led to complete recovery of renal function.
Conclusions: Our case illustrates a rare renal histological feature of CD. IL-6 and VEGF are postulated to suppress
glomerular VEGF expression, thereby causing renal TMA. Therapy directed against these inflammatory mediators
may have important therapeutic implications.
Keywords: Thrombotic microangiopathy, Castleman’s disease, VEGF, Podocytes
Background
Castleman’s disease (CD), first described in 1956, is an
uncommon lymphoproliferative disorder characterized
by focal or generalized lymphadenopathy [1]. Clinic-
ally, this group of lymphoproliferative disorders is
classified as unicentric CD (localized lymph node in-
volvement, UCD), or multicentric CD (diffuse lymph
node involvement, MCD). Systemic manifestations
commonly associated with MCD include fever, weight
loss, hepatosplenomegaly, ascites, edema, and anemia.
Histologically, there are three different variants of CD:
hyaline-vascular variant, plasma cell variant and mixed
variant. The hyaline-vascular variant accounts for 90%
of CD and is characterized by small hyaline vascular
follicles and interfollicular capillary proliferation. It is
typically associated with UCD and most patients exhibit
no symptoms. The plasma cell variant (9%) is character-
ized by hyperplastic follicles with interfollicular sheets of
plasma cells and is often associated with MCD.
Thrombotic microangiopathy (TMA) is a histopatho-
logical term for microangiopathic hemolytic anemia,
thrombocytopenia, and renal microvascular thrombosis.
Diagnostic TMA features include endothelial swelling in
glomerular capillaries and arterioles, mesangiolysis (dis-
solution or attenuation of mesangial matrix and degen-
eration of mesangial cells), and glomerular basement
membrane double contours (a feature of glomerular
basement membrane remodeling). The latter can be seen
without thrombi, which suggests subacute or chronic
TMA. Hemolytic uremic syndrome (HUS) and throm-
botic thrombocytopenic purpura (TTP) are two major
clinical entities comprising TMA with predominantly
renal manifestations in the former whereas neurological
and systemic manifestations in the latter, although
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overlap exists and differentiation of HUS from TTP is
not always possible.
Here, we present a complicated case of renal TMA in
a MCD patient in the absence of TTP/HUS. In the
presented patient, decreased podocyte expression of vas-
cular endothelial growth factor (VEGF) is linked to
TMA associated with CD.
Case presentation
A 19-year-old Caucasian male was transferred to Wash-
ington University Barnes-Jewish Hospital for evaluation
of acute renal failure (ARF) and previously diagnosed
TMA on renal biopsy. He presented with anasarca, mild
proteinuria, and diffuse lymphadenopathy. He was
initially admitted to a community hospital with diarrhea,
nausea, vomiting, generalized swelling, and low grade
fever for 3 weeks. There was no history of recent travel,
medication use or change in his home environment.
While in the community hospital, he was noted to have
new onset of thrombocytopenia and anemia without
evidence of hemolysis or schistocytes. Stool Shiga toxin
was negative, and stool cultures were negative for E. coli
O157:H7, Salmonella, Shigella, and Campylobacter.
Ascites was negative for peritonitis and malignancy, and
an inguinal lymph node core biopsy was reported as
nonspecific reactive hyperplasia.
Renal biopsy was performed and showed diffuse endo-
thelial swelling, mesangiolysis and thrombi within capil-
lary loops (Fig. 1, a-d). Occasional double contours were
present (Fig. 1c). There were no crescents, fibrinoid
necrosis, or significant fibrosis. Immunofluorescence (IF)
was negative for immune complex deposits. TMA was
diagnosed. ADAMTS 13 (a disintegrin and metallopro-
teinase with a thrombospondin type 1 motif, member 13)
activity was decreased (20%; normal levels, ≥67%). 10
sessions of plasmapheresis performed in the community
hospital did not improve his anemia, thrombocytopenia
and kidney dysfunction.
Fig. 1 Histopathological findings in renal and the inguinal lymph node biopsies from the patient with MCD. Renal (a-d) and lymph node biopsies (e-f)
at the onset of disease. a Diffuse endocapillary proliferation and endothelial swelling (Hematoxylin and eosin stain [H&E], ×400). b Thrombi within
capillary loops (arrow; Masson trichrome, ×200). c Mesangiolysis (arrow) and double contour (Jones Methenamine Silver, ×200). d Transmission
electron microscopy showed diffuse endothelial swelling with obliteration of capillary lumina and mesangial interposition (×4000). e Hyalinization of
the germinal center and concentric layering of peripheral lymphocytes (H&E, ×200). f Plasmacytosis highlighted with CD138 staining in the
interfollicular space is characteristic of plasma cell CD type (×200)
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On admission, tachycardia (109/min), hypertension
(148/86 mmHg), and normal body temperature were ob-
served. Conjunctivas were pale but not icteric. Respiratory
sounds were decreased bilaterally. The abdomen was
distended with free fluid. Lower extremities showed 1+
pedal edema, and lymph nodes were palpable in the axil-
lary and inguinal regions.
Laboratory evaluation revealed microcytic anemia
(hemoglobin 8.1 g/dL) and thrombocytopenia (platelets,
75,000/mm3) with lactate dehydrogenase and haptoglo-
bin being within normal range. The repeated peripheral
smear did not show schistocytes. Renal function had
deteriorated (blood urea nitrogen [BUN], 27 mg/dL;
serum creatinine [Cr], 2.18 mg/dL). The patient had nor-
mal liver function but with decreased total protein
(6.2 g/dL) and albumin (3.0 g/dL). Complement levels
were normal. Acute phase reactants including erythro-
cyte sedimentation rate (ESR, 59 mm/h; normal levels,
<12 mm/h), C-reactive protein (CRP, 99.4 mg/L; normal
levels, <9.9 mg/L) and ferritin (348 ng/ml; normal levels,
<322 ng/ml) were elevated. An increased IgG of
1560 mg/dl (normal range: 700–1450 mg/dl) with nor-
mal levels of IgA and IgM was found. There was no
monoclonal peak on immunoelectrophoresis in either
serum or urine. Autoantibodies including antinuclear
antibody (titer, 1:640) and anti-SS-A and anti-SS-B were
positive. Additionally, serum lupus anticoagulant was
positive, but β2 glycoprotein and anti-cardiolipin anti-
body were negative. Test results for hepatitis virus A, B
and C, human immunodeficiency virus, Epstein-Barr
virus, and cytomegalovirus were negative. Urinalysis
showed microhematuria without any casts and non-
nephrotic range proteinuria (683 mg/24 h).
Renal ultrasound showed normal size and echogenicity
of both kidneys. Computed tomography (CT) of the
chest, abdomen and pelvis showed retroperitoneal, mesen-
teric, pelvic, axillary and mediastinal lymphadenopathy as
well as hepatosplenomegaly, moderate ascites and small
bilateral pleural effusions.
An excisional lymph node biopsy performed in our
hospital showed follicular hyperplasia and diffuse inter-
follicular plasma cell infiltrate (Fig. 1 e–f ). Some of the
lymphoid follicles showed hyalinization of germinal cen-
ters and concentric layering of peripheral lymphocytes
(onion-skinning) in the mantle area (Fig. 1e). Immuno-
histochemistry revealed interfollicular plasmacytosis
demonstrated by CD138 staining (Fig. 1f ). HHV-8
immunostaining was negative. The patient’s diagnosis
was consistent with MCD, plasma cell variant. High cir-
culating level of VEGF (343 pg/ml; normal levels,
<86 pg/ml) was detected in this patient, a characteristic
feature of CD. Notably, double IF staining for VEGF and
the podocyte nucleus marker WT-1 showed that podo-
cyte VEGF expression was reduced in this patient com-
pared to healthy control (Fig. 2).
The patient was started on chemotherapy with Rituxi-
mab, Etoposide, Cyclophosphamide, Vincristine and
Prednisone for 6 cycles. Within a week of initiation of
chemotherapy, his renal function normalized. His clin-
ical symptoms such as fever, ascites and lymphadenop-
athy started improving. Anemia and thrombocytopenia
resolved, and markers of inflammation such as ESR and
CRP normalized within the first few weeks. The patient
has been free of symptoms for 2 years without taking
any medication.
Discussion
CD is a rare lymphoproliferative disorder. Renal involve-
ment has been only described in a limited number of
small studies. Based on a study conducted in a large CD
Fig. 2 Podocyte VEGF expression in healthy control kidney and renal biopsy from the CD-associated TMA patient. Formalin-fixed paraffin kidney
sections from control (a-c) and patient (d-f) were examined by dual IF staining of VEGF (red, a and d) and podocyte nucleus marker WT-1 (green,
b and e). Merged images for VEGF and WT-1 in c and f. Note the decreased podocyte VEGF expression in CD-associated renal TMA. Original
magnifications: ×400
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cohort of Chinese patients, renal involvement in CD is
about 25% [2], particularly seen in patients with MCD
plasma cell or mixed variant [2, 3]. ARF represents the
most common renal presentation, and glomerular
pathologies majorly include AA amyloidosis [3, 4], TMA
[2, 3, 5] and membranoproliferative glomerulonephritis
[6]. Other renal pathological findings include mesangio-
proliferative glomerulonephritis, interstitial nephritis [7],
membranous nephropathy [8], crescentic glomerulo-
nephritis [2, 9, 10], minimal change disease [2] and focal
segmental glomerulosclerosis [3]. Consistent with previ-
ous studies, our patient developed renal TMA in MCD
plasma cell variant, the aggressive type of CD.
The dysregulated production of VEGF and interleukin-
6 (IL-6) is implicated to play a central role in the patho-
genesis of CD. Proliferating plasma cells in lymph nodes
cause overproduction of both cytokines leading to
elevated systemic levels [11, 12]. VEGF exerts potent
pro-inflammatory effect and increases blood vessel per-
meability, which explains pleural effusion, ascites, and
generalized edema in our patient. IL-6 has pleotropic
effects, such as promoting B-cell differentiation to
immunoglobulin-producing plasma cells, stimulating
hepatocyte to synthesize acute-phase proteins, and indu-
cing dominance of Th17 cells over Tregs to disrupt
immune tolerance [13]. It has been shown that mice
overexpressing IL-6 produce a syndrome resembling CD
[14]. In our patient, IL-6 accounts for a variety of clinical
symptoms including generalized lymphadenopathy and
hepatosplenomegaly, polyclonal hypergammaglobuline-
mia, increased levels of ESR, CRP and ferritin, anemia,
and overproduction of autoantibodies.
Diffuse endothelial swelling, mesangiolysis and capil-
lary loop thrombi in combination with podocyte VEGF
downregulation in our patient resemble renal TMA seen
in cancer patients treated with VEGF inhibitors [15] or
preeclampsia patients with increased circulating level of
soluble fms-like tyrosine kinase 1 (sFlt1), a soluble VEGF
receptor and an antagonist of VEGF [16]. VEGF is a vas-
cular growth factor for vasculogenesis and angiogenesis
during development and in disease through regulation of
vascular permeability, endothelial cell migration, prolif-
eration, and cell survival [17]. VEGF released by podo-
cytes binds to VEGF receptors on glomerular
endothelial cells, resulting in receptor tyrosine phos-
phorylation and signal transduction. It has been demon-
strated that tight regulation of glomerular VEGF
signaling is critical for establishment and maintenance of
the glomerular filtration barrier. Moreover, it has been
shown that podocyte VEGF deletion in adult mice is suf-
ficient to trigger TMA by utilizing podocyte-specific
VEGF knockout mice [15, 18]. Previously, Karoui et al.
reported decreased glomerular VEGF expression in a
MCD patient with renal TMA [3]. However, co-
localization staining of glomerular VEGF with any
glomerular cell-specific marker was not performed.
The serum level of VEGF from the same affected
patient was also not examined. For the first time, we
performed dual IF staining of VEGF with the podo-
cyte nucleus marker WT-1 in the kidney biopsy and
correlated with serum VEGF level in our patient. Our
study showed podocyte VEGF downregulation associ-
ated with markedly elevated serum VEGF before
chemotherapy. The question of how persistent VEGF
and IL-6 overproduction leads to deficient podocyte
VEGF expression remains unresolved.
It is of note that not every CD patient develops renal
TMA. Genetic or acquired dysregulation of ADAMTS13
or the complement alternative pathway can predispose
patients to develop TMA. Deficiency of ADAMTS13,
owing to mutations in the ADAMTS13 gene or autoanti-
bodies that inhibit ADAMTS13 activity, can cause idio-
pathic TTP. It is not unusual for ADAMTS13 to be
decreased in TMA without TTP. In TTP, ADAMTS13
activity is typically <5% [19]. Therefore the TMA in our
patient does not appear to be caused by TTP, particu-
larly in the absence of hemolysis, schistocytes and
neurological symptoms. Dysfunction of the complement
alternative pathway, caused by mutations in complement
factor H, I, B, or membrane cofactor protein or by auto-
antibodies against factor H, can result in complement-
mediated TMA [20, 21]. The presented patient may have
mild complement abnormalities that increase his suscep-
tibility to develop renal TMA associated with CD.
In summary, we discuss a rare case of MCD patient
presenting with ARF, mild proteinuria and renal TMA.
The renal injury is associated with inhibited expression
of podocyte VEGF. In this patient, an excellent renal
response to chemotherapy was achieved. Reagents that
suppress overproduction of IL-6 and VEGF may lead to
highly-targeted treatments in CD. In addition, further
investigation to delineate the mechanism(s) involved in
podocyte VEGF downregulation will lead to discovery of
specific target molecules for the treatment of renal TMA
seen in CD.
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